Biomea Fusion is trading 6.1% up at $1.40 in pre-market on September 28; available evidence does not establish a specific cause. - The recent clinical-data timeline change and terminated offering were reported last week, not as new September 28 announcements. - Broader markets are under pressure amid renewed U.S.-Iran tensions, higher oil prices and elevated yields; this backdrop does not clearly explain the gain.